2026 Interim Report
Filed with HKEX · Stock code 2565 · · 62 pages · English
2 Corporate Information 4 Business Highlights 5 Financial Highlights 6 Management Discussion & Analysis 26 Corporate Governance and Other Information 40 Consolidated Statement of Profit or Loss and Other Comprehensive Income 41 Consolidated Statement of Financial Position 43 Consolidated Statement of Changes in Equity 44 Condensed Consolidated Statement of Cash Flows 45 Notes to the Unaudited Inte
Earlier from PegBio
- Change in use of proceeds from the global offering
- Proposed change of auditor
- Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
- Next Day Disclosure Return
- List of directors and their roles and functions
Later from PegBio
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- (1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
- Notice of the 2026 first extraordinary general meeting
- Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio